Report date: Mar 26, 2024 Conflict count: 356923 Publisher: Elsevier Title count: 938 Conflict count: 15183 ========================================================== Created: 2017-08-09 00:01:35.0 ConfID: 5271874 CauseID: 1409918735 OtherID: 1409918726, 1409918742 JT: Annals of Oncology MD: null, 8 ,11,1055,1997,News DOI: 10.1023/A:1017195131315(Journal) (5271874-N ) DOI: 10.1093/oxfordjournals.annonc.a010839(Journal) ========================================================== Created: 2020-01-07 18:08:20.0 ConfID: 5569733 CauseID: 1461029078 OtherID: 1461028985, 1461028990, 1461029034, 1461029048, 1461029050, 1461029051, 1461029054, 1461029055, 1461029073, 1461029074, 1461029079, 1461029080, 1461029078 JT: Annals of Oncology MD: null, 24 ,null,7,2013,No Abstract Available DOI: 10.1093/annonc/mdt042.1(Journal) (5569733-N ) DOI: 10.1093/annonc/mdt042.58(Journal) ========================================================== Created: 2020-01-07 20:19:22.0 ConfID: 5569736 CauseID: 1461037726 OtherID: 1461037727, 1461037724 JT: Annals of Oncology MD: null, 26 ,null,2,2015,No abstract available DOI: 10.1093/annonc/mdv080.1(Journal) (5569736-N ) DOI: 10.1093/annonc/mdv080.3(Journal) ========================================================== Created: 2020-01-07 20:19:52.0 ConfID: 5569737 CauseID: 1461037748 OtherID: 1461037745, 1461037748 JT: Annals of Oncology MD: null, 26 ,null,7,2015,No abstract available DOI: 10.1093/annonc/mdv083.4(Journal) (5569737-N ) DOI: 10.1093/annonc/mdv083.1(Journal) ========================================================== Created: 2020-01-07 20:20:12.0 ConfID: 5569738 CauseID: 1461037768 OtherID: 1461037766 JT: Annals of Oncology MD: null, 26 ,null,10,2015,No abstract available DOI: 10.1093/annonc/mdv085.5(Journal) (5569738-N ) DOI: 10.1093/annonc/mdv085.1(Journal) ========================================================== Created: 2020-01-07 20:20:22.0 ConfID: 5569739 CauseID: 1461037779 OtherID: 1461037775 JT: Annals of Oncology MD: null, 26 ,null,12,2015,No abstract available DOI: 10.1093/annonc/mdv086.1(Journal) (5569739-N ) DOI: 10.1093/annonc/mdv086.4(Journal) ========================================================== Created: 2020-01-07 20:20:27.0 ConfID: 5569740 CauseID: 1461037783 OtherID: 1461037777 JT: Annals of Oncology MD: null, 26 ,null,13,2015,No abstract available DOI: 10.1093/annonc/mdv087.2(Journal) (5569740-N ) DOI: 10.1093/annonc/mdv087.3(Journal) ========================================================== Created: 2020-01-07 20:20:42.0 ConfID: 5569741 CauseID: 1461037797 OtherID: 1461037795 JT: Annals of Oncology MD: null, 26 ,null,15,2015,No abstract available DOI: 10.1093/annonc/mdv089.4(Journal) (5569741-N ) DOI: 10.1093/annonc/mdv089.1(Journal) ========================================================== Created: 2020-01-07 22:26:44.0 ConfID: 5569743 CauseID: 1461045368 OtherID: 1461045365 JT: Annals of Oncology MD: null, 29 ,null,31,2018,WITHDRAWN DOI: 10.1093/annonc/mdy151.110(Journal) (5569743-N ) DOI: 10.1093/annonc/mdy151.112(Journal) ========================================================== Created: 2020-01-07 22:28:24.0 ConfID: 5569744 CauseID: 1461045469 OtherID: 1461045468 JT: Annals of Oncology MD: null, 29 ,null,49,2018,WITHDRAWN DOI: 10.1093/annonc/mdy151.173(Journal) (5569744-N ) DOI: 10.1093/annonc/mdy151.172(Journal) ========================================================== Created: 2020-01-08 00:14:35.0 ConfID: 5569748 CauseID: 1461053313 OtherID: 1409918806 JT: Annals of Oncology MD: Betticher, 8 ,11,1170,1997,Book review DOI: 10.1023/A:1008282204404(Journal) (5569748-N ) DOI: 10.1093/oxfordjournals.annonc.a010842(Journal) ========================================================== Created: 2020-01-08 00:18:26.0 ConfID: 5569749 CauseID: 1461053727 OtherID: 1402106720 JT: Annals of Oncology MD: null, 3 ,7,494,1992,News DOI: 10.1093/oxfordjournals.annonc.a058248(Journal) (5569749-N ) DOI: 10.1016/S0923-7534(19)65284-1(Journal) ========================================================== Created: 2020-01-09 17:37:38.0 ConfID: 5569905 CauseID: 1461227488 OtherID: 1461227486 JT: Annals of Oncology MD: Tahara, 23 ,null,81,2012,Novel Development of EGFR-Targeted Agents for Head and Neck Cancer DOI: 10.1016/S0923-7534(20)32183-9(Journal) (5569905-N ) DOI: 10.1016/S0923-7534(20)32184-0(Journal) ========================================================== Created: 2020-01-09 17:43:03.0 ConfID: 5569906 CauseID: 1461227860 OtherID: 1461227859 JT: Annals of Oncology MD: Morita, 23 ,null,131,2012,Association between Bevacizumab-Related Hypertension and VEGF Gene Polymorphisms in Japanese Colorectal Cancer Patients DOI: 10.1016/S0923-7534(20)32379-6(Journal) (5569906-N ) DOI: 10.1016/S0923-7534(20)32378-4(Journal) ========================================================== Created: 2020-02-27 12:49:35.0 ConfID: 5579094 CauseID: 1464121780 OtherID: 1347740507 JT: Annals of Oncology MD: Wheatley, 13 ,8,1319,2002,Adjuvant interferon for melanoma DOI: 10.1093/oxfordjournals.annonc.a000325(Journal) (5579094-N ) DOI: 10.1093/annonc/mdf224(Journal) ========================================================== Created: 2020-02-27 12:49:39.0 ConfID: 5579095 CauseID: 1464121798 OtherID: 1347740506 JT: Annals of Oncology MD: Punt, 13 ,7,1161,2002,D.P. Kelsen, J.M. Daly, S.E. Kern, B. Levin, J.E. Tepper (eds). Gastrointestinal Oncology, Principles and Practice DOI: 10.1093/oxfordjournals.annonc.a000324(Journal) (5579095-N ) DOI: 10.1093/annonc/mdf182(Journal) ========================================================== Created: 2020-05-18 20:27:44.0 ConfID: 5613481 CauseID: 1469723809 OtherID: 1469723808 JT: Annals of Oncology MD: Hosono, 28 ,null,409,2017,Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors DOI: 10.1093/annonc/mdx376.016(Journal) (5613481-N ) DOI: 10.1093/annonc/mdx376.017(Journal) ========================================================== Created: 2020-05-18 20:27:49.0 ConfID: 5613482 CauseID: 1469723813 OtherID: 1469723811 JT: Annals of Oncology MD: Aamdal, 28 ,null,410,2017,Telomerase peptide vaccine combined with ipilimumab in metastatic melanoma: Reports from a phase I trial DOI: 10.1093/annonc/mdx376.019(Journal) (5613482-N ) DOI: 10.1093/annonc/mdx376.020(Journal) ========================================================== Created: 2020-05-18 20:27:59.0 ConfID: 5613483 CauseID: 1469723821 OtherID: 1469723820 JT: Annals of Oncology MD: Wang, 28 ,null,412,2017,Meta-Analysis of Anti-PD-1/PD-L1 Therapy Related Adverse Events in Clinical Trials DOI: 10.1093/annonc/mdx376.025(Journal) (5613483-N ) DOI: 10.1093/annonc/mdx376.026(Journal) ========================================================== Created: 2020-05-18 20:28:09.0 ConfID: 5613484 CauseID: 1469723830 OtherID: 1469723829 JT: Annals of Oncology MD: Nguyen, 28 ,null,414,2017,Melanoma brain metastases patients treated with stereotactic radiosurgery and ipilimumab versus stereotactic radiosurgery alone: a systematic review with meta-analysis DOI: 10.1093/annonc/mdx376.033(Journal) (5613484-N ) DOI: 10.1093/annonc/mdx376.032(Journal) ========================================================== Created: 2020-05-18 20:28:34.0 ConfID: 5613485 CauseID: 1469723852 OtherID: 1469723848 JT: Annals of Oncology MD: Stanczak, 28 ,null,418,2017,Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy DOI: 10.1093/annonc/mdx376.045(Journal) (5613485-N ) DOI: 10.1093/annonc/mdx376.046(Journal) ========================================================== Created: 2020-05-18 20:29:09.0 ConfID: 5613486 CauseID: 1469723878 OtherID: 1469723877 JT: Annals of Oncology MD: Ott, 28 ,null,425,2017,An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder DOI: 10.1093/annonc/mdx376.068(Journal) (5613486-N ) DOI: 10.1093/annonc/mdx376.067(Journal) ========================================================== Created: 2020-05-18 20:29:14.0 ConfID: 5613487 CauseID: 1469723882 OtherID: 1469723879 JT: Annals of Oncology MD: Wilkins, 28 ,null,426,2017,A first-in-human, open-label, multicenter phase 1/2a study to evaluate the safety and efficacy of increased repeated doses of the first in class RORĪ³ agonist LYC-55716 in treating locally advanced or metastatic solid tumors DOI: 10.1093/annonc/mdx376.069(Journal) (5613487-N ) DOI: 10.1093/annonc/mdx376.070(Journal)